N
Google TrendNOVIG (2000+) — Novig Sign Up Bonus: ROTOWIRE Gets $50 in Trade Credits
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:novig2000+boise state vs fresno state500+sounders500+pedro pascal200+medicare2000+blade200+kings vs golden knights1000+white sox vs cleveland guardians match player stats1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Biogen to Acquire Apellis" (30 stories)

Top Headline Story

Biogen Completes Acquisition of Apellis Pharmaceuticals
Lead StoryBiogengeneral
May 14

Biogen Completes Acquisition of Apellis Pharmaceuticals

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOZ256enZtNjcySFlVRFVBdlVmVlIxLVFUYVZGVVJCMWJyaEVwaG1XSFdrOWxZU3ZDWGtiZmVUNkRtSmtKeTIyaldoQ2xuQ3JzaXdQeUNteGZOM3hZYzI5UUJ0MXVYNDBjVGZrSldQQUFSaF9MUUphR1lyX3daMl9pODJkdGU1NWRLM0NLRDlvelJmOEkzYV92VkY1TE1qWEFXV3dyWW1FeGJObnowT0VfUlRISFR0YXc?oc=5" target="_blank">Biogen Completes Acquisition of Apellis Pharmaceuticals</a>  <font color="#6f6f6f">Biogen</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
2000+24m ago

novig

Novig Sign Up Bonus: ROTOWIRE Gets $50 in Trade Credits

Filter stories
500+24m ago

boise state vs fresno state

Boise State gets big health boost, but injury concerns remain vs. Fresno State

Filter stories
500+24m ago

sounders

NEvsSEA Starting XI: Dejan Joveljić and Yeimar return to starting lineup, Sebastian Gomez gets the nod

Filter stories
200+24m ago

pedro pascal

Pedro Pascal in ‘Behemoth!’: The Oscar-Worthy Role That He (and Latinos) Have Been Waiting For

Filter stories

Search Results for "Biogen to Acquire Apellis"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Biogen completes acquisition of Apellis Pharmaceuticals
Ophthalmology Timesgeneral

Biogen completes acquisition of Apellis Pharmaceuticals

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPNXJMNVJXX0t6M0xBVkJMTC1tN3hEXzhFYi1paGlnZWh4Z3Z5VUgwNFpHUE5BeDJKbm9abjdsZVU0aXBiRVVCQ3BJYldIem90b1JpUXhKMlpuTVFCQ29pWHJaZUhRRFN1alA2cDR2djV5c284OTBoVkNGSjluV1Q0WlRSYXZvTTh3bmpVaHZtY2xmbFNUZVdIU3pQcw?oc=5" target="_blank">Biogen completes acquisition of Apellis Pharmaceuticals</a>  <font color="#6f6f6f">Ophthalmology Times</font>

Read Full StoryMore like this
Biogen, eyeing swift commercial tailwind, ponies up $5.6B for Apellis and its 2 approved meds
Fierce Pharmatech

Biogen, eyeing swift commercial tailwind, ponies up $5.6B for Apellis and its 2 approved meds

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxON0VVaThPbURMR05NNnZfbUc2UEVxVGN1TEFSamp4dGRSMGlxU2NBSnptMXkwa3A5dXl1WldMNHlXeUNFSC1QZTNjTjJUV1MyZ3pKMUZYbEVXVWY5alhlM3BsSjRpMmpGd0hKcC03NFJRZFAwbngzaGZIM0hjUkhRQllkSEU5Mkl6UmFsRW9IOEFiLWlMWlQtcjlacUh2eDRHTHlGdGM0TGdPaktYRkFVVlc0ZTQ2VjBsaWFTNUdR?oc=5" target="_blank">Biogen, eyeing swift commercial tailwind, ponies up $5.6B for Apellis and its 2 approved meds</a>  <font color="#6f6f6f">Fierce Pharma</font>

Read Full StoryMore like this
Biogen bets on $5.6 billion buyout of Apellis in rare disease push
Reuterspolitics

Biogen bets on $5.6 billion buyout of Apellis in rare disease push

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxObGE4cUZOT2NCT1IxVG1USzBQTUJMeklqRWIyTFBSWGMxdElQMGl1VmRvYlVuZV9JSzlldDczLXhsNV9IcG9GR3R5am9nMnpORkFrWXBVNFBiSXBRSHdSaHZtVklIOEp3aXhhLWpfRWRsWjJLV3l6UjFocGhPbG5jOUNlbnFudk9zY3RXWVpWYlVORWdjQ0FUUFlwRlBIVk1Zemlr?oc=5" target="_blank">Biogen bets on $5.6 billion buyout of Apellis in rare disease push</a>  <font color="#6f6f6f">Reuters</font>

Read Full StoryMore like this
Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion
WSJpolitics

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOVDNwTmlKZDdsdlZPelM2d1ZXamFwUXpmOFdKbUE2SnZoVTVTbDFGMHN2SU52Mlp5aVVTLXJpTEdFc1YzVzNDRllLc2FpY0NlTDJtUHItYl9fd1I2RTc0blB3SXpFeG5fMWNzNklqM1FSQnNPay1pN0U1QUhGUW9ncC1GZGNJbVh0TWFwZkZaakUwMnZILWQxdzBxN09zeF8z?oc=5" target="_blank">Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion</a>  <font color="#6f6f6f">WSJ</font>

Read Full StoryMore like this
Biogen to acquire immunology biotech Apellis for $5.6 billion
STATtech

Biogen to acquire immunology biotech Apellis for $5.6 billion

<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE9vcXRHd0ZqNzIyOWFyOHZ2QUhTSUFfaWdtaGhpTmIxeEg5enJiRm1sd2ZjMllKcHc2NkNTb0FvVmxETngtZkozaFQ1UzBncnFPS2RTM29JNWZxNHJsdzFONnZNUDhVTWNHY3pXWGMzWm51Y2duZlhXZktlNjN1Tnc?oc=5" target="_blank">Biogen to acquire immunology biotech Apellis for $5.6 billion</a>  <font color="#6f6f6f">STAT</font>

Read Full StoryMore like this
Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals
Pharmaceutical Executivepolitics

Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxNMlJ1RkJBdV9qbXZlc0d3WnJpSnZiVjFjaXdtUUFxRDduNm9qbUNvb1hPRWd3VkJMaktGMnhKaUdCN3MzZlpfVm1NZ1p6Q3ZwZVp5YTIyTUtDd05XdFpBdmdhRmRjR05pWjhYbDhsTEdoRDdoRWEzRFdEQnZWbTJRenVnNUd4NzA?oc=5" target="_blank">Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals</a>  <font color="#6f6f6f">Pharmaceutical Executive</font>

Read Full StoryMore like this
Biogen shifts M&A strategy as Apellis acquisition pushes revenue above analyst expectations
BioSpacegeneral

Biogen shifts M&A strategy as Apellis acquisition pushes revenue above analyst expectations

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQemptTjI5eEV5N0h6MHVzYVRqOE1HZXBjYjdJdXFJZjZEajFtT3lxNDA0OXBESDh6ejJ2RXpVLXc1Q0tUZEljWVduYkN3UVhHQnZGTmpFRXQ1VTlvTHhVV3IwSl9iMm0wSExvOEhOY05uTTBEdHBkTGdBeWJIeV8tSXdicm1BdktaaG5Pa0xLTkNFVE5BTUVpNjRDejBCendGV2VCU05ZTFZMdGpMQXJyVW9TVVppTEZfNzl0cmdDXzVlSjA?oc=5" target="_blank">Biogen shifts M&A strategy as Apellis acquisition pushes revenue above analyst expectations</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets
BioPharma Divegeneral

Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOUGlPNlp0d1JzV1ZFMGF4QnMybGZhT0RPV3FzejlGV3VLUERlbkJLTURpeUdQSGExZ3I5NXdtb3ZWY2g5eFM4TmdSUzBLb0hCb1Fqano0cndWanVIemVGR3JvX3pPRFRNaW5ZRE45S2ItbXlxektlMElCcUIteTdjYWR4RWhwVzBKc2EwVm03cFE4MFNaeElZV3dfbGZmR2FUOGhjTUFGR3FaWVpjZDR3Q3dWMVY1VVg2NDBwZE1GMUh2VUtrYlE?oc=5" target="_blank">Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets</a>  <font color="#6f6f6f">BioPharma Dive</font>

Read Full StoryMore like this
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Biogenworld

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOVEV0VlhLbzVMaGdWYjJJLVN4V0NIVnVidDk2NW9vRzVpTTNwVDBZTl9aQW9Xd0FKQ3JTeXBvcUZpSTFQNHEwN3NRX1FTeUdfdVNlYWpDZlREb1lOd0RVemRNUG5WRnlHN3R1czVXN2NteVFqeV9hYzZybXZZWVkwTDZSNlFrQmJtNFBOUjZqZU9jRXFRRmFhNE1oNkVfM1ZrWEFIZ2FQclpuYmRYV09jVDdGSDZKZ1BPYnhXZHNIZw?oc=5" target="_blank">Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology</a>  <font color="#6f6f6f">Biogen</font>

Read Full StoryMore like this
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio
Yahoo Financeworld

Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNbkgxd19FOVhaM2VJREhscDJwek04TWNnTmZFTGV5cjcxZHNHU1J0QVpSYTZ6X0xHR0R2aGNQRVpwSC1WaDFoSkV5d2dLcV91MVlET19XdldGYnZ2TVpldmhsa25uNktoMFFiVE03TkQxUXV6LTRMR0c2RDlnNXJSYWRaUkVfMnoxTnlWbU9LYTA2UFFkbC1Cd1N6Wmk?oc=5" target="_blank">Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Biogen ends Apellis research programs, cuts ‘small number’ of roles after $5.6B buyout
Fierce Biotechgeneral

Biogen ends Apellis research programs, cuts ‘small number’ of roles after $5.6B buyout

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNdi1HVlB2Rk51ZXFQQm5zcmZVM0U5cGtyb0hUTmR1OVg2Um9wQzFiYlRUd3UySzBEQmhWQlpZOUYzRm9DLVR4cTMxWFpmalZoZDN1dFNVMG5OS0pQZ2pRT3NzUlZYMW84bHNjZ1Bvcm8xbU1ScVlqWVctRndGaEg4UE55MUxRVzFaamplcFE1SlliMFZLbGUtdWJJaUphZUhGaUxxOGpqVlV3TUhVa0JHc09Wbi1IWjg?oc=5" target="_blank">Biogen ends Apellis research programs, cuts ‘small number’ of roles after $5.6B buyout</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
Biogen trims Apellis pipeline and R&D team after $5.6bn takeover
Pharmaceutical Technologygeneral

Biogen trims Apellis pipeline and R&D team after $5.6bn takeover

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxObENLSzV2dW04MllMMXBETl9IVTVxa0p4NXd4cDByNXVxTnVYOEVzZ3FEQkRlcVctTTZjM2toSVlSQzF0Yjh0QU9yN19ENzY2VFRiRi1sUF9xY0xHVVBlSThfSGFFa3lwd1lrY3V4YzY5ek5uWmtmbmYxc0Q2VTVCVHlLTUFxT3Jlc1REcFJ4MW1yVVRFTGgzUXpYREk3eTg?oc=5" target="_blank">Biogen trims Apellis pipeline and R&D team after $5.6bn takeover</a>  <font color="#6f6f6f">Pharmaceutical Technology</font>

Read Full StoryMore like this
Biogen to buy Apellis Pharmaceuticals for $5.6 billion in rare disease push
CNBCpolitics

Biogen to buy Apellis Pharmaceuticals for $5.6 billion in rare disease push

<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE94NnRjQzAtcXdjQkpVa2FpYlRmR01DNkd0U2lNZmNpb1NnczlHOWNqMmNfeHpDTHpjbDBqV2JsbTVrNncyZktyMVpELXg5azF1UUdTaGZVV3hGNVlkSGlvTDZPbThScm1PMnJBdDR1YlJVYnhBeXYtdjlqN0x2Y0HSAYQBQVVfeXFMTXBPUVNaZC1mclJIUGtpMlcwOVBlX25UOXhWekR2ZE5qbFBFLXdhMVVwVUI2Rkxrb21LVURNS0VVdW55Y0I1cTdteExrZDZjalJzaHppdEdqQmtGTEFQZUNlU0xjME1raU83MzJPTnpBZ0t5aDBVRUxEaGF3eEJOYXdtQ0NW?oc=5" target="_blank">Biogen to buy Apellis Pharmaceuticals for $5.6 billion in rare disease push</a>  <font color="#6f6f6f">CNBC</font>

Read Full StoryMore like this
Why Biogen Is Paying $5.6B to Buy Apellis Pharma
MedCity Newsgeneral

Why Biogen Is Paying $5.6B to Buy Apellis Pharma

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxQVll0dml1NGViZVZKR2k1MTRaSjdmTi1tMi13REN6SlQzWE5fZ2VMMk85ODRkQlFXVl9LYy1TRFgzVzRXcTd2UWRNUVBILS1TRHo1cDRhSGJTZkV0RkFITjdTcVBzNVRWRXUxWnJmLUdubm9vVUlLTlJZSDEtLXk5RFl0YXhwYms?oc=5" target="_blank">Why Biogen Is Paying $5.6B to Buy Apellis Pharma</a>  <font color="#6f6f6f">MedCity News</font>

Read Full StoryMore like this
Biogen to acquire Apellis in $5.6 billion deal
Ophthalmology Timespolitics

Biogen to acquire Apellis in $5.6 billion deal

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxOVDh3dnlNZVhZUWFucm5ldlo5VjNKMlhVYnJ2TGZCeXFtWkVTN25La0JyRlJjQXJqYXNaSEc3V1FHbXdZNUh6RXdVMmMzT0VlX0pBeF9xeHBHdldWUW04dlJQdW1wd0lFdmx4ejM4LXJsOXNvcmVjTEZjTmFPQmtidDlJMW5pV1lEOVhYOXBn?oc=5" target="_blank">Biogen to acquire Apellis in $5.6 billion deal</a>  <font color="#6f6f6f">Ophthalmology Times</font>

Read Full StoryMore like this
Biogen, with $5.6B Apellis buy, builds out immunology offerings
BioPharma Diveworld

Biogen, with $5.6B Apellis buy, builds out immunology offerings

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxONFVtbDBLZ2hxS19mNlR5NTdkZjRxQnEtY3dhMGtFVlRmb0prZzBJeENSMlZXVUNfMlRydjN4Ym05dl9kV0RmWlFNWGplclBWLUJZYVBTbGFLQnN0STdUYkpEYTc4NVQyNml5ZlNkaGhuRjdyeFZYSi1HbnB3QUxXQ04wVzkyQkxlMVlidEJzTkVQOFZ3T01vN2J0MXlFYjQ?oc=5" target="_blank">Biogen, with $5.6B Apellis buy, builds out immunology offerings</a>  <font color="#6f6f6f">BioPharma Dive</font>

Read Full StoryMore like this
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio
Yahoo Financegeneral

Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQZzdtSDN3LVRGMkhaeWU0MXJZYTNFYU9uRVYyRFFfNlNfSjV4akR5MUVtVWF4OHh1aUlEcVpsdVEyNjI0R1JzclZQSU5WYkpJanRtdnMzdmRKR1BDMDhCRkVZSlByTjhhWmZ5OHhBWWxHUllwRGdCOE4wbzZUVU9WVU9namNrZ0FnZnRIa0ltcTM0aWtNMFIwaU5fUzhHWlNsS2tieWRGRWFoUjdBNWc?oc=5" target="_blank">Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy
BioSpaceworld

Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNbDJ3LUVwWFVocHdXak83eTYtd0N3YjNYZE1kNmI1NjFkRDlubkhGQkhweW1tZ1o0aTVhTGZOU295LU5xblJnTHZWWnE1c1FNSnVlMTMyTGl2V3hBRDRjTkstTC03S2hsX2c5V3h5QVhnY012YnBuMV9jclFfUXZlVmRlQXczdkVqc3pMbDV3Qm9ZSlowTTNlU0dmei16QUhaYlpTVQ?oc=5" target="_blank">Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Biogen’s Apellis Deal Reshapes Growth Outlook And Valuation Story
Yahoo Financegeneral

Biogen’s Apellis Deal Reshapes Growth Outlook And Valuation Story

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPeGZJYmNMWWlPZFctSkFuS0N2azY3SmNYbEU3YVpFTWt2RzVSLVVRR2JRaFB4LXFyczlfZ1hJb1oxclZfa3hpMjJ6cldlYVZ5YWtRVC1JZnVaaG1iYlRQYXMxU0RQRmN4QkUtdUJsS1kxRW5HcnNjLUU5UUVFTzBBQ2Nzdm1CMVJWSFplUjl4VGRfcTY2ZmJFSUp0U2FjNURyX1E?oc=5" target="_blank">Biogen’s Apellis Deal Reshapes Growth Outlook And Valuation Story</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout
Pharmaceutical Technologygeneral

Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPTXF5ZkhubVVKN194RTFsX2hrMDk3RGZxTW14el9PRngzTG53NUMwMXAzazY5SGJPZGt2d2hvRlQxcE9RX0JfX25nTHZpQnZiaVAzUnl2TlFyRmw5eV9zNHlmemNEQm1PaTRtNGNtNGpwZ1E0dkh3UWRVQXpPXzlvQlZPYUR6N083ZTh5R2RGaWpJMDZQRllOQw?oc=5" target="_blank">Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout</a>  <font color="#6f6f6f">Pharmaceutical Technology</font>

Read Full StoryMore like this
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout
Reuterspolitics

Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout

<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxPeXI5MDYyMEM2R2UzOVlnTEZaSmw1dDlCMnl0WlpDZUU1amtkdEotNm51TWMyOHhnZFdHSURlTk9Kd21jTjVUQm5aTTJzVjB3TkpaNGNINjBERHBRNzRxNWNlOXlXd1owUVhpRlphMTVLR2xmYkh3RVNHRS1LazFXWkJOd2xBQkZlbnItRHpvREdKWHZ1bTg0TWxPb0RVcnpMc2wyXzlOeXhJMzk2YW9UYmZkeXdFQ3FnekFGSGR2bFBhLXZNM3pqOGRrTEstRnZKV19nc1ZnM3U1ejJZbThQYTJfRFF2VkE?oc=5" target="_blank">Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout</a>  <font color="#6f6f6f">Reuters</font>

Read Full StoryMore like this
Biogen to acquire Apellis in $5.6bn deal
PMLiVEgeneral

Biogen to acquire Apellis in $5.6bn deal

<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTFBnNnFneFBqOTJYdmZLV29vREVoZDFoZVRxSkxySjY3c015alp2MWJFZnBCejRLUWZ0Ml9Kd2pJOU9jTGFjUUN4dXRHejl5amdDM2tGWEw0QkVwcGJTc2N6YWRzeWwzcmNVeGpMcU02UlNobmtNQWV4U0pnUQ?oc=5" target="_blank">Biogen to acquire Apellis in $5.6bn deal</a>  <font color="#6f6f6f">PMLiVE</font>

Read Full StoryMore like this
Biogen to acquire Apellis for $5.6bn
Financier Worldwidegeneral

Biogen to acquire Apellis for $5.6bn

<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE15N0lFbXhaMV82WC0wZGZXVl9Hb21qN1A2cGc2dVZIOUViLUcxT2VCMHdmUVo5WHlEaVlPNEJnX3UzU29Hel9ZQ1p6YjFUYmpRYy1QZlkwa3RoNHJqNEtzbEp5OXIwNXh6eHlpQ3ZwZ2lKS3FtYldFeA?oc=5" target="_blank">Biogen to acquire Apellis for $5.6bn</a>  <font color="#6f6f6f">Financier Worldwide</font>

Read Full StoryMore like this
After buying Apellis for $5.6B, Biogen is cutting most of its pipeline work
Endpoints Newsgeneral

After buying Apellis for $5.6B, Biogen is cutting most of its pipeline work

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxONUJKU0hBNk5zM0cyT3hET21acDFYT0NXeGdlcTQtNE1sc1NUZC1JRFVyREtfNkFQakluOGRLNkhuaUU1YWQzdVp4VVN1NkNTMVBjX1FKRFA2MnY4amVSUkYwaG5EckkxWjA0dUc4clhFUFdKMUxqVklmdnB3anVkTTlSc3o5bk04WnpYd3FmbTJfZkVLUjJmUy1DdEtBUQ?oc=5" target="_blank">After buying Apellis for $5.6B, Biogen is cutting most of its pipeline work</a>  <font color="#6f6f6f">Endpoints News</font>

Read Full StoryMore like this
Biogen completes $5.3B Apellis Pharmaceuticals acquisition
Quartzgeneral

Biogen completes $5.3B Apellis Pharmaceuticals acquisition

<a href="https://news.google.com/rss/articles/CBMiaEFVX3lxTE82b2I1Rl9FNHVyazNiNnFSa1ExUEJQUWo4TVdCZ3VNOF9SSEo0WUxCSVF1bmthSXJkWTRsbENoYllOVU9laEkzWUprRm5LbUlUUWJkYUdoU283RTZPVEcyUVVNOFRucEgt?oc=5" target="_blank">Biogen completes $5.3B Apellis Pharmaceuticals acquisition</a>  <font color="#6f6f6f">Quartz</font>

Read Full StoryMore like this
Biogen bets newly acquired Apellis can paper over Leqembi's disappointing sales into 2027
Endpoints Newsgeneral

Biogen bets newly acquired Apellis can paper over Leqembi's disappointing sales into 2027

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOeTVCUWxNY09FcmpEWElWUXVXRThkT0xGSXR0TV9SRWJkREt6ZS1DbVE1Zy1pY1RTeFNnWFBZN042Nk5UMkVpVlAzWkxwdkFJNzNNV1BBYnlXWG13bzNfZjZUTEY0WW0zTGN0Z3ZjUkRxanBzeFJQTDJTdTRFS0RTM1g4SkRjd1ZmWm1IYkNhQXpNNUpEOTh2OQ?oc=5" target="_blank">Biogen bets newly acquired Apellis can paper over Leqembi's disappointing sales into 2027</a>  <font color="#6f6f6f">Endpoints News</font>

Read Full StoryMore like this
Updated: Biogen highlights kidney disease ambitions in $5.6B Apellis buyout
Endpoints Newsgeneral

Updated: Biogen highlights kidney disease ambitions in $5.6B Apellis buyout

<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTFB2dWJab0NUZ1dzbURYazJOdzJTSTMxQkx5S1ZUU3JaZU9GTGI3X1Y0S3o2X1VqQXhISjFWRTFTcWpGUW1STFhtdFM0SHdBMnRiblNXZ3MyR1ZCX3VOaDZkSUVFMnI?oc=5" target="_blank">Updated: Biogen highlights kidney disease ambitions in $5.6B Apellis buyout</a>  <font color="#6f6f6f">Endpoints News</font>

Read Full StoryMore like this
Biogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise
Bloomberg.compolitics

Biogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOa1pUNWRyWTFWMl9sRk9GTDhkNW5YWVZQRWQ2enRTbGpIb0JxZzlxUDBNdE9QTmtJMHpVeFBNZnN0SHNmQmNqdUxseFB4QkMzRTY2Q1pnMFIwV0hpdDFmTDFEUXlIalZhYTZfSmlqODU2b0I2UjNNcVRtdFN0ZDVpdGVTblZPUzdVdWhTOEJTR19XWmdlSFA1VzNiLUFTU3NtNTRfVEZXbWFFbmxwWFhwZjl4SGo?oc=5" target="_blank">Biogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise</a>  <font color="#6f6f6f">Bloomberg.com</font>

Read Full StoryMore like this
Biogen Expands Complement Disease Portfolio Through Acquisition of Apellis Pharmaceuticals
BioPharm Internationalgeneral

Biogen Expands Complement Disease Portfolio Through Acquisition of Apellis Pharmaceuticals

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOV01lMEJiVGh1dm5Ja2VOcXR0QmY3WkQyRlFCSmt6UUotZ3FtSDhNb29GeHZXSzB3MWVFRUx4N1BKRGdoV3A1cXFfcktsSUlUUUlMdVJVUURvQlBCU1R6WHhFQTN1WGN2OFA3QUxyU3hBVWNNWDBBXzhQWlpRMFVodHZBcWhNUUxHNGhGTzgxVmV3dVZ2bW14akx4REpTdzVLbmhMWVdWVU1hV3F5a2VDU0p5XzVvNDRHbk1sUVlvUG1CdDVtNFFpWTlScDk4Zw?oc=5" target="_blank">Biogen Expands Complement Disease Portfolio Through Acquisition of Apellis Pharmaceuticals</a>  <font color="#6f6f6f">BioPharm International</font>

Read Full StoryMore like this
"Biogen to Acquire Apellis" — Live Google News Trends & Headlines